Recent Foundation Releases
-
Foundation Fighting Blindness Announces Leadership Changes
Press ReleasesJason Menzo named chief executive officer • Russell Kelley, PhD, MBA, appointed managing director of the RD Fund • Ben Yerxa, PhD, to lead Opus Genetics, the first RD Fund- and Foundation-backed spin-off company.
-
Foundation Fighting Blindness to Host VISIONS 2022 Conference
Press ReleasesThe national conference will be held on June 17–18, featuring sessions with the latest research advancements, practical adapting and thriving, and an opportunity to connect with the blind and low vision community.
-
Press Releases
The Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for retinal degenerative diseases, will host an online continuing medical education (CME and COPE) course on inherited retinal disease gene therapies on Thursday, June 9, 2022, at 7:00 p.m. EDT.
-
Press Releases
Trial recruitment is enabled by the Foundation Fighting Blindness’ patient registry, My Retina Tracker® Registry, which includes genetic and vision information for more than 20,000 people with inherited retinal diseases.
-
Press Releases
The March 6th virtual event will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.
-
Press Releases
Commitment to expand translational research acceleration program and fund career development award.
-
Foundation Fighting Blindness Promotes Jason Menzo to President and Chief Operating Officer
Press ReleasesNoteworthy Foundation executive increases role within organization.
-
Press Releases
Program to have special translational research emphasis on inherited macular dystrophy.
-
Press Releases
This December 16th exclusive in-person performance and conversation with the Blind Boys of Alabama will raise awareness for blinding diseases.
-
RD Fund Announces Fundraising Efforts Underway for RD Fund 2
Press ReleasesPatient-centric venture philanthropy model continues to invest in companies developing therapies for individuals affected by retinal degenerative diseases.
